losartan potassium · Scienture · NDA 218772
Arbli
Earliest generic entry, as listed
7 Oct 2041
Blocked by patent: US 11890273, US 12156869, US 12605365.
Listed patents · 3 unexpired
6 Orange Book listing rows for 3 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 11890273 | drug product · sets the listed date | 7 Oct 2041 |
| US 12156869 | drug product, use U-4158, U-4159, U-4160 | 7 Oct 2041 |
| US 12156869 listing row | drug product, use U-4158 · sets the listed date | 7 Oct 2041 |
| US 12156869 listing row | drug product, use U-4159 · sets the listed date | 7 Oct 2041 |
| US 12156869 listing row | drug product, use U-4160 · sets the listed date | 7 Oct 2041 |
| US 12605365 | drug product, use U-4159, U-4160 | 7 Oct 2041 |
| US 12605365 listing row | drug product, use U-4159 · sets the listed date | 7 Oct 2041 |
| US 12605365 listing row | drug product, use U-4160 · sets the listed date | 7 Oct 2041 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 218772 · 001 · RLD | suspension, oral | 10MG/ML | 7 Oct 2041 |